vs
Side-by-side financial comparison of TrueBlue, Inc. (TBI) and Bio-Techne (TECH). Click either name above to swap in a different company.
TrueBlue, Inc. is the larger business by last-quarter revenue ($418.2M vs $311.4M, roughly 1.3× Bio-Techne). On growth, TrueBlue, Inc. posted the faster year-over-year revenue change (8.3% vs -1.5%). Over the past eight quarters, TrueBlue, Inc.'s revenue compounded faster (1.9% CAGR vs 1.3%).
The Blue Bird Corporation is an American bus manufacturer. Headquartered in Fort Valley, Georgia, the company was best known for its production of school buses. The company has also manufactured a wide variety of other bus types, including transit buses, motorhomes, and specialty vehicles such as mobile libraries and mobile police command centers.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
TBI vs TECH — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $418.2M | $311.4M |
| Net Profit | — | $51.0M |
| Gross Margin | 21.5% | 66.9% |
| Operating Margin | -7.0% | 24.2% |
| Net Margin | — | 16.4% |
| Revenue YoY | 8.3% | -1.5% |
| Net Profit YoY | — | 126.0% |
| EPS (diluted) | $-1.06 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $311.4M | ||
| Q4 25 | $418.2M | $295.9M | ||
| Q3 25 | $431.3M | — | ||
| Q2 25 | $396.3M | $317.0M | ||
| Q1 25 | $370.3M | $316.2M | ||
| Q4 24 | $386.0M | $297.0M | ||
| Q3 24 | $382.4M | $289.5M | ||
| Q2 24 | $396.2M | $306.1M |
| Q1 26 | — | $51.0M | ||
| Q4 25 | — | $38.0M | ||
| Q3 25 | $-1.9M | — | ||
| Q2 25 | $-160.0K | $-17.7M | ||
| Q1 25 | $-14.3M | $22.6M | ||
| Q4 24 | — | $34.9M | ||
| Q3 24 | $-7.6M | $33.6M | ||
| Q2 24 | $-104.7M | $40.6M |
| Q1 26 | — | 66.9% | ||
| Q4 25 | 21.5% | 64.6% | ||
| Q3 25 | 22.7% | — | ||
| Q2 25 | 23.6% | 62.7% | ||
| Q1 25 | 23.3% | 67.9% | ||
| Q4 24 | 26.6% | 65.3% | ||
| Q3 24 | 26.2% | 63.2% | ||
| Q2 24 | 26.4% | 66.4% |
| Q1 26 | — | 24.2% | ||
| Q4 25 | -7.0% | 18.4% | ||
| Q3 25 | -0.0% | — | ||
| Q2 25 | -0.7% | -7.5% | ||
| Q1 25 | -3.8% | 12.2% | ||
| Q4 24 | -2.7% | 16.0% | ||
| Q3 24 | -1.8% | 13.8% | ||
| Q2 24 | -15.1% | 15.0% |
| Q1 26 | — | 16.4% | ||
| Q4 25 | — | 12.8% | ||
| Q3 25 | -0.4% | — | ||
| Q2 25 | -0.0% | -5.6% | ||
| Q1 25 | -3.9% | 7.1% | ||
| Q4 24 | — | 11.7% | ||
| Q3 24 | -2.0% | 11.6% | ||
| Q2 24 | -26.4% | 13.3% |
| Q1 26 | — | $0.32 | ||
| Q4 25 | $-1.06 | $0.24 | ||
| Q3 25 | $-0.06 | — | ||
| Q2 25 | $-0.01 | $-0.11 | ||
| Q1 25 | $-0.48 | $0.14 | ||
| Q4 24 | $-0.41 | $0.22 | ||
| Q3 24 | $-0.26 | $0.21 | ||
| Q2 24 | $-3.45 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.5M | $209.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $274.6M | $2.1B |
| Total Assets | $638.7M | $2.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $209.8M | ||
| Q4 25 | $24.5M | $172.9M | ||
| Q3 25 | $19.9M | — | ||
| Q2 25 | $21.9M | $162.2M | ||
| Q1 25 | $23.1M | $140.7M | ||
| Q4 24 | $22.5M | $177.5M | ||
| Q3 24 | $14.5M | $187.5M | ||
| Q2 24 | $26.4M | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M |
| Q1 26 | — | $2.1B | ||
| Q4 25 | $274.6M | $2.0B | ||
| Q3 25 | $304.3M | — | ||
| Q2 25 | $305.2M | $1.9B | ||
| Q1 25 | $302.2M | $2.0B | ||
| Q4 24 | $315.4M | $2.1B | ||
| Q3 24 | $327.2M | $2.1B | ||
| Q2 24 | $337.8M | $2.1B |
| Q1 26 | — | $2.6B | ||
| Q4 25 | $638.7M | $2.5B | ||
| Q3 25 | $690.5M | — | ||
| Q2 25 | $672.8M | $2.6B | ||
| Q1 25 | $692.5M | $2.6B | ||
| Q4 24 | $675.4M | $2.7B | ||
| Q3 24 | $702.4M | $2.7B | ||
| Q2 24 | $723.7M | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.4M | — |
| Free Cash FlowOCF − Capex | $-7.5M | — |
| FCF MarginFCF / Revenue | -1.8% | — |
| Capex IntensityCapex / Revenue | 0.7% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-73.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-4.4M | — | ||
| Q3 25 | $-19.8M | — | ||
| Q2 25 | $-11.8M | $98.2M | ||
| Q1 25 | $-22.1M | $41.1M | ||
| Q4 24 | $6.1M | $84.3M | ||
| Q3 24 | $-7.1M | $63.9M | ||
| Q2 24 | $-1.8M | $75.5M |
| Q1 26 | — | — | ||
| Q4 25 | $-7.5M | — | ||
| Q3 25 | $-23.4M | — | ||
| Q2 25 | $-16.1M | $93.3M | ||
| Q1 25 | $-26.8M | $31.0M | ||
| Q4 24 | $854.0K | $77.5M | ||
| Q3 24 | $-12.7M | $54.7M | ||
| Q2 24 | $-7.7M | $57.5M |
| Q1 26 | — | — | ||
| Q4 25 | -1.8% | — | ||
| Q3 25 | -5.4% | — | ||
| Q2 25 | -4.0% | 29.4% | ||
| Q1 25 | -7.2% | 9.8% | ||
| Q4 24 | 0.2% | 26.1% | ||
| Q3 24 | -3.3% | 18.9% | ||
| Q2 24 | -2.0% | 18.8% |
| Q1 26 | — | — | ||
| Q4 25 | 0.7% | — | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 1.1% | 1.5% | ||
| Q1 25 | 1.3% | 3.2% | ||
| Q4 24 | 1.4% | 2.3% | ||
| Q3 24 | 1.5% | 3.2% | ||
| Q2 24 | 1.5% | 5.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.82× | ||
| Q4 24 | — | 2.42× | ||
| Q3 24 | — | 1.90× | ||
| Q2 24 | — | 1.86× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TBI
| People Scout | $187.7M | 45% |
| Other | $175.0M | 42% |
| Healthcare Staffing Professionals Inc. | $55.5M | 13% |
TECH
| Protein Sciences segment revenue | $226.2M | 73% |
| Diagnostics and Spatial Biology segment revenue | $85.6M | 27% |
| Other revenue (1) | $5.4M | 2% |
